EMA Tackles How To Substantiate New Active Substance Claims For Biologics & ATMPs
Executive Summary
The European Medicines Agency is seeking feedback on its position on assessing whether biological substances and advanced therapy medicinal products qualify for NAS status.
You may also be interested in...
Pharma Worried By EMA’s Stricter Approach To New Active Substance Claims For Biologics
EFPIA says the European Medicines Agency’s proposed criteria for determining “new active substance” status for biologicals may encourage subjective assessments and result in a higher standard for grant of the status.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug
The CHMP, the European Medicines Agency’s human medicines committee, will this week decide whether a range of new medicines merit being approved.